Trials / Completed
CompletedNCT01959919
Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 86 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate prospectively throughout a period of 3- 6 months and not to exceed 12 months (according to local therapeutic plans) patients experiences of treatment with Factor VIII in the new device named FuseNGO, a new delivery system for Factor VIII compared to their previous delivery system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Refacto FusENGO | Dosage will be chosen by PI based on patient condition. |
Timeline
- Start date
- 2014-01-27
- Primary completion
- 2016-12-12
- Completion
- 2016-12-12
- First posted
- 2013-10-10
- Last updated
- 2018-09-25
- Results posted
- 2018-09-25
Locations
19 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01959919. Inclusion in this directory is not an endorsement.